USANA Health Sciences (NYSE:USNA) Upgraded by Zacks Research to Hold Rating

USANA Health Sciences (NYSE:USNA) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of USNA opened at $20.61 on Monday. USANA Health Sciences has a 1 year low of $18.48 and a 1 year high of $38.32. The stock has a market capitalization of $376.75 million, a PE ratio of 23.42, a PEG ratio of 0.95 and a beta of 0.67. The stock has a 50-day simple moving average of $20.72 and a 200-day simple moving average of $23.64.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. The firm had revenue of $226.20 million for the quarter, compared to analyst estimates of $225.96 million. Analysts predict that USANA Health Sciences will post 2.45 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of USANA Health Sciences in the second quarter valued at approximately $274,000. Allianz Asset Management GmbH purchased a new stake in USANA Health Sciences in the 2nd quarter valued at $638,000. Connor Clark & Lunn Investment Management Ltd. raised its position in USANA Health Sciences by 202.3% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,537 shares of the company’s stock valued at $2,978,000 after purchasing an additional 65,268 shares during the last quarter. AlphaQuest LLC boosted its stake in USANA Health Sciences by 168.1% during the 2nd quarter. AlphaQuest LLC now owns 9,146 shares of the company’s stock worth $279,000 after purchasing an additional 5,734 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in USANA Health Sciences by 497.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 47,204 shares of the company’s stock worth $1,300,000 after purchasing an additional 39,297 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.